The maker of Ozempic and Wegovy saw £70billion wiped off its value yesterday as fierce competition in the fat jab market took its toll.
Shares in Novo Nordisk fell as much as 30 per cent after it slashed sales and profits forecasts for the second time this year amid pressure from Mounjaro and Zepbound maker Eli Lilly.
The Danish company also appointed a new chief executive after abruptly ousting former boss Lars Fruergaard Jorgensen in May following a dramatic slump in the share price.
New boss Maziar Mike Doustdar – Novo’s head of international operations – faced a baptism of fire yesterday as the latest bleak trading update sent shares to a three-year low.
The stock is now down more than 60 per cent since peaking in June last year – slashing its value from £460billion to £177billion.
It marked another difficult day for Novo chairman Helge Lund, who last week faced the humiliation of being removed from the same job at energy giant BP earlier than he hoped.
Slim pickings: Shares in Ozempic and Wegovy maker Novo Nordisk fell as much as 30% after it slashed sales and profits forecasts for the second time this year
Chris Beauchamp, chief market analyst at trading platform IG, said: ‘Novo Nordisk shares continue to endure their own remarkable weight-loss programme.
‘The pendulum has swung from wild optimism a year ago to rampant pessimism now. Are there any investors brave enough to snap up a possible bargain?’
Copenhagen-listed Novo became Europe’s most valuable listed firm after the launch of Wegovy in 2021. At one point, it was larger than the Danish economy.
But shares have plunged in the past year over concerns about its drug pipeline and its waning strength in the US, the largest market for weight-loss medication.
Although Zepbound was launched more than two years after Wegovy, prescriptions of the Eli Lilly drug now outstrip those of Novo’s blockbuster by more than 100,000 a week.
Zepbound is marketed as Mounjaro in the UK where it has been dubbed the ‘King Kong’ of slimming jabs.
Novo yesterday said it expects sales to rise by between 8 per cent and 14 per cent this year – down from a previous range of 13 per cent to 21 per cent.
It also lowered its forecasts for profit growth to as little as 10 per cent from a previous estimate of up to 24 per cent.
Minutes after the bleak update, Novo revealed Doustdar will be taking the helm on August 7.
He said: ‘The fact that my announcement comes right after the update just makes the mandate ahead even more clear.’
DIY INVESTING PLATFORMS
AJ Bell
AJ Bell
Easy investing and ready-made portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free fund dealing and investment ideas
interactive investor
interactive investor
Flat-fee investing from £4.99 per month
InvestEngine
InvestEngine
Account and trading fee-free ETF investing
Trading 212
Trading 212
Free share dealing and no account fee
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.
This article was originally published by a www.dailymail.co.uk . Read the Original article here. .